1. Infectives Vaccine Partnering Terms and Agreements
The Infectives vaccine partnering terms and agreements report provides a detailed understanding and analysis
of how and why companies enter infectives vaccine partnering deals. The majority of deals are development
stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These
deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The
report also includes adjuvant deals and alliances.
This report provides details of the latest infectives vaccine agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight
into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst
many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of
how payments are triggered – contract documents provide this insight where press releases and
databases do not.
This report contains a comprehensive listing of all infectives vaccine partnering deals announced since
January 2007, including financial terms where available, including over 300 links to online deal records of
actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include
contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have a significant impact on each
party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company? What exclusivity is granted? What are
the precise rights granted or optioned? What is the payment structure for the deal? How aresalesand payments
audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and
owned? Who is responsible for commercialization? Who is responsible for development, supply, and
manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what
conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing
and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which
jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an
orientation of infectives vaccine dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an overview of the trends in infectives vaccine dealmaking since 2007,
including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading infectives vaccine deals since 2007. Deals are listed by headline
value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the
deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive and detailed review of infectives vaccine partnering deals signed and
announced since January 2007, where a contract document is available in the public domain. The chapter is
organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal
Infectives Vaccine Partnering Terms and Agreements

2. record and where available, the contract document, providing easy access to each contract document on
demand.
The report also includes numerous tables and figures that illustrate the trends and activities in infectives
vaccine partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development and commercialization of infectives
vaccine technologies and products.
Report scope
Infectives Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding
and access to infectives vaccine trends and structure of deals entered into by leading companies worldwide.
Infectives Vaccine Partnering Agreements includes:
Trends in infectives vaccine dealmaking in the biopharma industry since 2007 Analysis of infectives vaccine
deal structure Access to headline, upfront, milestone and royalty data Access to over 600 cancer vaccine deal
records The leading infectives vaccine deals by value since 2007 Includes adjuvant and drug delivery deals
and alliances since 2007
In Infectives Vaccine Partnering Agreements, the available deals are listed by:
Company A-Z Headline value Stage of development at signing Deal component type Specific oncology
therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
The Infectives Vaccine Partnering Agreements report provides comprehensive access to available deals and
contract documents for over 600 infectives vaccine deals. Analyzing actual contract agreements allows
assessment of the following:
What are the precise rights granted or optioned? What is actually granted by the agreement to the partner
company? What exclusivity is granted? What is the payment structure for the deal? How aresalesand payments
audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and
owned? Who is responsible for commercialization? Who is responsible for development, supply, and
manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what
conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing
and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction
does the company insist upon for agreement law? Benefits
In-depth understanding of dental deal trends since 2007 Access dental deal headline, upfront, milestone and
royalty data Research hundreds of actual contracts between dermatology partner companies Comprehensive
access to over 1500 links to actual dermatology deals entered into by the world’s biopharma companies
Indepth review of dental deals entered into by the leading fifty bigpharma companies Benchmark the key deal
terms companies have agreed in previous deals Identify key terms under which companies partner
dermatology opportunities Uncover companies actively partnering dermatology opportunities Report scope
Dermatology Partnering Terms and Agreements is intended to provide the reader with an in-depth
understanding and access to dermatology trends and structure of deals entered into by leading companies
worldwide.
Dermatology Partnering Terms and Agreements includes:
Trends in dermatology dealmaking in the biopharma industry since 2007 Analysis of dermatology deal
structure Access to headline, upfront, milestone and royalty data Access to hundreds of dermatology deal
Infectives Vaccine Partnering Terms and Agreements

3. contract documents Comprehensive access to over 1500 dermatology deal records The leading dermatology
deals by value since 2007 Most active dermatology dealmakers since 2007 In Dermatology Partnering Terms
and Agreements, available deals and contracts are listed by: Headline value o Upfront payment value Royalty
rate value o Stage of development at signing Deal component type Technology type Specific therapy
indication Each deal title links via Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
table Of Contents
executive Summary
chapter 1 – Introduction
chapter 2 – Trends In Infectives Vaccine Dealmaking
2.1. Introduction
2.2. Infectives Vaccine Partnering Over The Years
2.3. Bigpharma Infectives Vaccine Dealmaking Activity
2.4. Bigpharma Not Active In Infectives Vaccine Partnering
2.5. Infectives Vaccine Partnering By Deal Type
2.6. Infectives Vaccine Partnering By Stage Of Development
2.7. Infectives Vaccine Partnering By Infectives Indication
2.8. Disclosed Deal Terms For Infectives Vaccine Partnering
2.8.1 Infectives Vaccine Partnering Headline Values
2.7.2 Infectives Vaccine Deal Upfront Payments
2.7.3 Infectives Vaccine Deal Milestone Payments
2.7.4 Infectives Vaccine Royalty Rates
chapter 3 – Leading Infectives Vaccine Deals
3.1. Introduction
3.2. Top Infectives Vaccine Deals By Value
chapter 4 – Infectives Vaccine Dealmaking Directory
4.1. Introduction
4.2. Company A-z
4.3. By Stage Of Development
discovery
marketed
phase I
Infectives Vaccine Partnering Terms and Agreements

4. phase Ii
phase Iii
pre-clinical
4.4. By Deal Type
asset Purchase
assignment
bigpharma Outlicensing
co-development
collaborative R&d
co-market
contract Service
co-promotion
crada
cross-licensing
development
distribution
equity Purchase
evaluation
grant
joint Venture
licensing
manufacturing
marketing
material Transfer
option
promotion
research
royalty Financing
settlement
spin Out
sub-license
supply
technology Transfer
termination
warranty
4.5. By Infectives Therapy Area
infectives
4.6. By Related Technology
vaccines
chapter 5 –partnering Resource Center
5.1. Online Partnering
Infectives Vaccine Partnering Terms and Agreements

5. 5.2. Partnering Events
5.3. Further Reading On Dealmaking
appendices
appendix 1 – Deal Type Definitions
appendix 2 – Example Infectives Vaccine Partnering Agreement
about Wildwood Ventures
current Partnering
current Agreements
current Reports
recent Report Titles From Currentpartnering
order Form – Therapy Reports
About Us:
Transparency Market Research is a market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of
Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
ResearchMoz
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Blog: http://researchmoz.blogspot.com/
Website: http://www.researchmoz.us/
Infectives Vaccine Partnering Terms and Agreements